腔内Epodyl用于治疗多发性非侵袭性、高分化膀胱肿瘤。

Intracavitary Epodyl for multiple non-invasive, highly differentiated bladder tumours.

作者信息

Colleen S, Ek A, Hellsten S, Lindholm C E

出版信息

Scand J Urol Nephrol. 1980;14(1):43-5. doi: 10.3109/00365598009181188.

Abstract

Multiple, recurrent cancer of the bladder grade I-II (WHO), stage T1 (UICC) was treated with regular intravesical instillation of ethoglucid (Epodyl) in 39 patients. In ten of them cystitis necessitated withdrawal of the treatment. The therapeutic schedule could be followed in 29 cases, with eradication of the tumours in 27. Nine patients who continued the treatment on a prophylactic basis were still recurrence-free after 18-60 (mean 37) months. Myelosuppression did not occur, but cystitis was a serious problem that frequently jeopardized therapy.

摘要

39例患有I-II级（世界卫生组织）、T1期（国际抗癌联盟）的多发性复发性膀胱癌患者接受了乙环氧啶（Epodyl）膀胱内定期灌注治疗。其中10例因膀胱炎而不得不停止治疗。29例患者能够遵循治疗方案，27例肿瘤得以根除。9例在预防性基础上继续治疗的患者在18至60个月（平均37个月）后仍无复发。未发生骨髓抑制，但膀胱炎是一个严重问题，经常危及治疗。